Mestrelab > Screen

Screen

Automatic analysis tool for ligand screening NMR data.

Simple and efficient tool, with flexible analysis and reporting features, already used by Top Pharma companies. Mnova Screen can handle all of the data from the following screening experiments:

  • 1H or 19F
  • Single compounds or mixtures
  • With or without reference spectra
  • Single or multiple types of spectra (STD, T1rho, WaterLogsy, CPMG)
  • Use of Blank, w/ Protein, & w/ Protein+ Inhibitors

You can read more information in this Mnova Screen overview and also request the latest webinar given in collaboration with Bruker.

 

CHECK WHAT'S NEW IN MNOVA SCREEN 1.3 HERE

Data review and spectrum comparison reduced to a ‘human reviewed’ automated process.

Mnova Screen: 45-day FREE trial

product_icon_download 1. Download

Screen is a plugin integrated in Mnova. No extra installer is required.

product_icon_install 2. Installation

Open Mnova and go to ‘Help/Get-Install Licenses’. Select ‘Evaluate’.

product_icon_license 3. License

Fill in the form to receive your trial license via e-mail.

Help & Resources

product_icon_guidesResources

product_icon_manuals Articles

product_icon_videos Videos

BROWSE ALL RESOURCES FOR THIS PRODUCT

SCREEN

Highlights

Data review and spectrum comparison reduced to a ‘human reviewed’ automated process.

  • Pattern recognition algorithms map your experimental data.
  • Considers the use of STD, wLOGSY, T1rho, CMPG experiments.
  • Uses deconvolution to effectively pick peak even weak signals.
  • Result viewer to quickly inspect your hits.
  • Export metrics of your analysis into your favorite statistical package.

Academic, Government & Industrial

Markets

  • Structural biology, biophysics and NMR groups in pharmaceutical companies.
  • Target based drug discovery and NMR groups in academic and research institutions.
  • CRO’s and service providers for target based lead detection and lead optimization.

Success Stories

Case Studies

A successful collaboration with Novartis on automated analysis of ligand-observed 1H-19F NMR binding data for fragment based lead generation
May 15, 2017 | | Case Studies NMR, Case Study Screen | 0 Comments

Several groups in Novartis use NMR binding assays to find and validate hits during the early stages of drug discovery. They use ligand-observed NMR experiments such as STD, T1ρ, and CPMG to identify library compounds that interact with a target protein. Until a few years ago, the analysis of a high number of complex spectra was performed largely manually and therefore represented a limiting step in hit generation campaigns. Read More